TY - JOUR
T1 - New treatment options for hearing loss
AU - Müller, Ulrich
AU - Barr-Gillespie, Peter G.
N1 - Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/5/5
Y1 - 2015/5/5
N2 - Hearing loss is the most common form of sensory impairment in humans and affects more than 40 million people in the United States alone. No drug-based therapy has been approved by the Food and Drug Administration, and treatment mostly relies on devices such as hearing aids and cochlear implants. Over recent years, more than 100 genetic loci have been linked to hearing loss and many of the affected genes have been identified. This understanding of the genetic pathways that regulate auditory function has revealed new targets for pharmacological treatment of the disease. Moreover, approaches that are based on stem cells and gene therapy, which may have the potential to restore or maintain auditory function, are beginning to emerge.
AB - Hearing loss is the most common form of sensory impairment in humans and affects more than 40 million people in the United States alone. No drug-based therapy has been approved by the Food and Drug Administration, and treatment mostly relies on devices such as hearing aids and cochlear implants. Over recent years, more than 100 genetic loci have been linked to hearing loss and many of the affected genes have been identified. This understanding of the genetic pathways that regulate auditory function has revealed new targets for pharmacological treatment of the disease. Moreover, approaches that are based on stem cells and gene therapy, which may have the potential to restore or maintain auditory function, are beginning to emerge.
UR - http://www.scopus.com/inward/record.url?scp=84929025734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929025734&partnerID=8YFLogxK
U2 - 10.1038/nrd4533
DO - 10.1038/nrd4533
M3 - Review article
C2 - 25792261
AN - SCOPUS:84929025734
SN - 1474-1776
VL - 14
SP - 346
EP - 365
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 5
ER -